Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01905709

Fecal Microbiota Transplantation for C Diff Infection

The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI). It has been shown that good bacteria (like that found in the stool from a healthy donor) attack Clostridium difficile in multiple ways: they make substances that kill Clostridium difficile - and they attach to the surface of the colon lining, which prevents the Clostridium difficile toxin (poison) from attaching.

FMT involves infusing a mixture of saline and stool from a healthy donor into the bowel of the patient with CDI during a colonoscopy.

The method used to deliver the FMT will depend on individual characteristics of the subject and is at the discretion of the treating physician. FMT may be administered by the following methods.

* Colonoscopy: This method allows full endoscopic examination of the colon and exclusion of comorbid conditions (such as IBD, malignancy or microscopic colitis) which may have an impact on subject's treatment or response to therapy. * Sigmoidoscopy: This method still allows infusion of the stool into a more proximal segment of the colon than an enema, but may not require sedation. This method may be beneficial in subjects who are elderly or multiparous and who may have difficulty retaining the material when given as enema. Sigmoidoscopic administration eliminates the additional risks associated with colonoscopy in subjects who may not have a clear indication for colonoscopy. * Retention enema: This method may be preferable in younger subjects who have already had recent endoscopic evaluation, in subjects who prefer not to undergo endoscopy or in subjects with significant co morbidities and may not tolerate endoscopy.

The physician will administer 300-500 mL of the fecal suspension in aliquots of 60 mL, through the colonoscope or sigmoidoscope or 150 mL via retention enema. In cases of colonoscopic delivery, the material will be delivered to the most proximal point of insertion.

The subject is encouraged to retain stool for as long as possible.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Englewood Hospital and Medical Center

Englewood, New Jersey, 07631, United States

Location status: Recruiting

Location contact

Dara Herman

CONTACT

[email protected]

Irina Kaplounov, MD

SUB_INVESTIGATOR

Marc Fiorillo, MD

CONTACT

[email protected]

201-945-6564

Marc Fiorillo, MD

PRINCIPAL_INVESTIGATOR

Mark Sapienza, MD

SUB_INVESTIGATOR

Michael Meininger, MD

SUB_INVESTIGATOR

Mtichell Spinnell, MD

SUB_INVESTIGATOR

Sandarsh Kancherla, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is at least 18 years old.
  • Subject has recurrent or relapsing CDI defined as:
  • At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin). OR
  • At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity. OR
  • Moderate CDI not responding to standard therapy (vancomycin) for at least a week. OR
  • Severe C. difficile infection with toxic megacolon, not responding to standard therapy or the use of IVIg.
  • Subject is willing and able to provide informed consent.
  • If a female of childbearing potential, subject has agreed to use an acceptable form of birth control for up to 4 weeks after FMT treatment.

Exclusion criteria

  • Subject is pregnant.
  • Subject is unable to comply with study requirements.

Treatment and study plan

Human fecal matter

Biological

Other names: human stool

Primary outcomes

  1. CDI recurrence

    Time frame: 8 weeks

    Number of patients who did/did not experience relapse in the 8 weeks post FMT

Study contacts

Contact information is provided by the study sponsor or research team.

Marc Fiorillo, MD

CONTACT

[email protected]

201-945-6564

Rosabel Cascina

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Englewood Hospital and Medical Center

Other

Registry information

Official study title

Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)

Important dates

Study start
2013
Primary completion
2026
Study completion
2026
First posted
Jul 23, 2013
Registry last updated
Apr 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.